Unity Health Toronto

Anju Philip

Xiao-Yan Wen

Claudia Dossantos

John Marshall

The present disclosure relates generally to treatment and diagnosis of diseases, disorders or conditions characterized by vascular leakage. More particularly, the present disclosure relates to methods for treating a vascular leakage-associated disease or disorder in a subject; for reducing vascular leakage in a subject; for reducing reactive oxygen species production in a subject; for inducing apoptosis of neutrophils in a subject; and for increasing survival of a subject having a vascular leakage-associated disease or disorder. The methods comprise administering a G9a and/or G9a-like protein (GLP) methyltransferase inhibitor to the subject. The present disclosure further relates to methods for developing a treatment plan for a subject with a vascular leakage-associated disease, disorder or condition, and for identifying a subject as a candidate for treatment of a vascular leakage-associated disease or disorder. The present disclosure relates to use of G9a and/or G9a-like protein (GLP) methyltransferase inhibitor in the treatment of vascular leakage-associated disease, disorder or condition.

Growing community of inventors

Richmond Hill, Canada

Anju Philip